In 2013, cancer immunotherapy was named “Breakthrough of the Year” by Science [21] partly due to the clinical success of blocking antibodies against programmed cell death protein 1 (PD-1) and PD-L1 in different cancers [22]. This evidence concerns the gene PDCD1 and cancer.